Verici Dx PLC Lorenzo Gallon, MD, Appointed as Chair of S.A.B
13 Septiembre 2021 - 1:01AM
RNS Non-Regulatory
TIDMVRCI
Verici Dx PLC
13 September 2021
Verici Dx plc
("Verici Dx" or the "Company")
Lorenzo Gallon, MD, Appointed as Chair of Science Advisory
Board
Verici Dx plc (AIM: VRCI), a developer of advanced clinical
diagnostics for organ transplant, announces the appointment of
Lorenzo Gallon, MD, as Chair of the Company's Science Advisory
Board (SAB). Dr. Gallon was appointed to the Company's Board as a
Non-executive Director on 19 August 2021.
A Professor of Medicine (Nephrology and Hypertension) and
Surgery (Organ Transplantation), Dr. Gallon is currently the
Medical Director of the Translational Medicine Programme, the
Director of International Relations and the Director of the Renal
Transplant Fellowship at Northwestern University. He is an alumnus
of the University of Padua Medical School, Italy and Harvard
Medical School.
An expert in nephrology and hypertension as well as organ
transplantation, Dr. Gallon's primary research interests
include:
-- The role of immunosuppressive medications in modulating the immune system,
-- Genomics of chronic renal allograft rejection,
-- Prednisone-free and calcineurin inhibitors-free immunosuppressive protocols,
-- New immunosuppressive strategies,
-- Focal segmental glomerulosclerosis (FSGS), and
-- Aging and impact of physical exercise after kidney transplantation.
With nearly 20 years' experience in the life sciences industry,
focusing largely on nephrology and organ transplantation, Dr.
Gallon is excellently placed to provide insight and guidance in the
development of Verici's two lead products, Clarava(TM) and
Tuteva(TM). He was a collaborator and co-author with Verici's
previous SAB Chair, Dr. Barbara Murphy, in the GoCar study(1) which
was foundational in the development of Verici's products. He has
also been a member of the Editorial Board at the journal Nephron
since 2019.
In 2012, Dr Gallon was part the Northwestern Medicine transplant
team that conducted the first successful removal and implantation
of a kidney from one patient to another after the organ failed in
the first recipient. The findings of the case were published in the
New England Journal of Medicine.
Julian Baines, MBE, Non-executive Chairman of Verici Dx,
said:
"I am delighted to welcome Lorenzo as the new Chair of Verici
Dx's Science Advisory Board. As a leading expert in nephrology and
organ transplantation, he has been hugely valuable on the Board so
far, and I'm sure will become even more so in this additional role,
helping us accelerate development of our two lead products,
Clarava(TM) and Tuteva(TM)."
Dr Lorenzo Gallon, Non-executive Director of Verici Dx,
said:
"I am pleased to take on this additional role with Verici Dx, as
Chair of the Science Advisory Board. I have been impressed with the
progress of its product portfolio, which has the potential to
really improve outcomes for kidney transplant patients, and look
forward to working more closely with the team to provide advice and
some experience to help advance the products."
(1) - https://pubmed.ncbi.nlm.nih.gov/27452608/
Enquiries:
Verici Dx www.v ericidx .com
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser Tel: 020 7496 3000
& Broker)
Aubrey Powell / Tom Salvesen
Walbrook PR Limited Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502 558 258
About Verici Dx plc www.vericidx.com
Verici Dx is an immuno-diagnostics company developing and
commercialising tests to understand how a patient will respond and
is responding to organ transplant, with an initial focus on kidney
transplants. The body's own immune system poses a threat to a
successful transplant or graft. Patients' immune systems differ in
how they respond to the presence of the transplanted organ.
Characterising this response and those of other biological pathways
enables the development of RNA signatures for prognostic and
diagnostic tests. Our products and solutions are underpinned by
extensive scientific research into the recipient's RNA signatures
and how that impacts on acute rejection, chronic injury and
ultimately failure of the transplant. These RNA signatures may also
inform clinicians as to the optimal strategy for immunosuppressive
and other therapies for the most successful treatment to ensure
graft acceptance with the least amount of side effects.
The foundational research was driven by a deep understanding of
cell-mediated immunity and is enabled by access to expertly curated
collaborative studies in highly informative cohorts in kidney
transplant.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUUSARAUUKAUR
(END) Dow Jones Newswires
September 13, 2021 02:01 ET (06:01 GMT)
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024